199 related articles for article (PubMed ID: 17383232)
1. Classic and novel roles of p53: prospects for anticancer therapy.
Fuster JJ; Sanz-González SM; Moll UM; Andrés V
Trends Mol Med; 2007 May; 13(5):192-9. PubMed ID: 17383232
[TBL] [Abstract][Full Text] [Related]
2. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
3. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
4. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
6. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
Chari NS; Pinaire NL; Thorpe L; Medeiros LJ; Routbort MJ; McDonnell TJ
Apoptosis; 2009 Apr; 14(4):336-47. PubMed ID: 19229632
[TBL] [Abstract][Full Text] [Related]
7. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
Resnick-Silverman L; Manfredi JJ
J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation.
Kutuk O; Arisan ED; Tezil T; Shoshan MC; Basaga H
Carcinogenesis; 2009 Sep; 30(9):1517-27. PubMed ID: 19578044
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
10. Stress-induced p53 runs a transcription-independent death program.
Erster S; Moll UM
Biochem Biophys Res Commun; 2005 Jun; 331(3):843-50. PubMed ID: 15865940
[TBL] [Abstract][Full Text] [Related]
11. [Role of the p53 and bcl-2 genes in apoptosis and drug resistance of tumors].
Luk'ianova NIu; Kulik GI; Chehun VF
Vopr Onkol; 2000; 46(2):121-8. PubMed ID: 10853407
[No Abstract] [Full Text] [Related]
12. p53: prospects for cancer gene therapy.
Soddu S; Sacchi A
Cytokines Cell Mol Ther; 1998 Sep; 4(3):177-85. PubMed ID: 9825843
[TBL] [Abstract][Full Text] [Related]
13. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
Huerta S; Heinzerling JH; Anguiano-Hernandez YM; Huerta-Yepez S; Lin J; Chen D; Bonavida B; Livingston EH
J Surg Res; 2007 Sep; 142(1):184-94. PubMed ID: 17603079
[TBL] [Abstract][Full Text] [Related]
14. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells.
Park SE; Lee SW; Hossain MA; Kim MY; Kim MN; Ahn EY; Park YC; Suh H; Kim GY; Choi YH; Kim ND
Cancer Lett; 2008 Oct; 270(1):77-86. PubMed ID: 18554781
[TBL] [Abstract][Full Text] [Related]
15. Death squads enlisted by the tumour suppressor p53.
Michalak E; Villunger A; Erlacher M; Strasser A
Biochem Biophys Res Commun; 2005 Jun; 331(3):786-98. PubMed ID: 15865934
[TBL] [Abstract][Full Text] [Related]
16. Transcription-independent p53 apoptosis: an alternative route to death.
Speidel D
Trends Cell Biol; 2010 Jan; 20(1):14-24. PubMed ID: 19879762
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria in cancer cells: what is so special about them?
Gogvadze V; Orrenius S; Zhivotovsky B
Trends Cell Biol; 2008 Apr; 18(4):165-73. PubMed ID: 18296052
[TBL] [Abstract][Full Text] [Related]
18. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
Puca R; Nardinocchi L; Bossi G; Sacchi A; Rechavi G; Givol D; D'Orazi G
Exp Cell Res; 2009 Jan; 315(1):67-75. PubMed ID: 18996371
[TBL] [Abstract][Full Text] [Related]
19. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
20. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
